Human activated protein C variants in a rat model of arterial thrombosis

Karl Malm¹, Björn Arnljots¹ and Björn Dahlbäck*²

Address: ¹Department of Clinical Sciences, Division of Reconstructive Surgery, Lund University, University Hospital, SE-20502 Malmö, Sweden and ²Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, University Hospital, SE-20502 Malmö, Sweden

Email: Karl Malm - karl.malm@med.lu.se; Björn Arnljots - bjorn.arnljots@med.lu.se; Björn Dahlbäck* - bjorn.dahlback@med.lu.se

* Corresponding author

Abstract

Background: Activated protein C (APC) inhibits coagulation by degrading activated factor V (FVa) and factor VIII (FVIIIa), protein S (PS) functioning as a cofactor to APC.

Methods: By mutagenesis of the vitamin K-dependent Gla domain of APC, we have recently created an APC variant having enhanced anticoagulant activity due to increased affinity for negatively charged phospholipid membranes. In the present study, the potential antithrombotic effects of this APC variant, and of a variant APC that is additionally mutated in the serine protease domain, have been evaluated in a blind randomized study in a rat model of arterial thrombosis. In this model, we have previously found the combination of bovine APC and PS to be highly antithrombotic. Four treatment groups each containing 10 rats were, in a blind random fashion, given intravenous bolus injections of wild-type or mutant variants of APC (0.8 mg/kg) together with human PS (0.6 mg/kg) or human PS (0.6 mg/kg) alone. A control group with 20 animals was given vehicle only.

Results: A trend to increased patency rates was noted in a group receiving one of the APC variants, but it did not reach statistical significance.

Conclusion: In conclusion, administration of human APC variants having enhanced anticoagulant efficacy together with human PS in a rat model of arterial thrombosis did not give an efficient antithrombotic effect. The lack of effect may be due to species-specific differences between the human protein C system and the rat hemostatic system.

Background

Activated protein C (APC) is an endogenous anticoagulant, which is crucially important for the regulation of blood coagulation [1-6]. APC is generated by limited proteolysis of its zymogen protein C by thrombin bound to its cofactor thrombomodulin on the surface of intact endothelium. APC effectively down-regulates the coagulation processes by selectively degrading the activated coagulation cofactors factor V (FVa) and factor VIII (FVIIIa). Protein S (PS) is a cofactor to APC in the regulation of FVa and FVIIIa. The importance of protein S as a cofactor in the anticoagulant protein C system is illustrated by the increased risk of venous thrombosis in individuals with a hereditary deficiency of the protein [7,8]. The molecular mechanisms involved in the enhancement by PS in the APC-reactions are incompletely understood. PS has been
suggested to increase the affinity of APC to phospholipid membranes [9] but also to alter the orientation of the active site of APC [10].

Because of its powerful anticoagulant features and selective action, APC is interesting to evaluate for therapeutic intervention and APC has been shown to have antithrombotic features in different animal thrombosis models. Thus, human APC (hAPC) is highly effective in non-human primates [11-15]. Bovine APC (bAPC) is also highly antithrombotic in arterial thrombosis models in rabbits and rats, but only when co-administered with bovine protein S (bPS), demonstrating the importance of PS as a cofactor to bAPC and the species specificity in the APC-PS interaction [16-19]. The results using hAPC in rat models are more divergent. Earlier work showed antithrombotic effects of even low doses of hAPC in different models of thrombosis in the rat [20-24]. However, we have been unable to demonstrate any antithrombotic effects of hAPC in an arterial thrombosis model in rats [25]. This model is dependent on both primary hemostasis and on activation of blood coagulation, as indicated by the antithrombotic effects of active-site inhibited FVIIa, heparin and the combination of bovine APC and bovine protein S [19,26,27].

Recently, we have created recombinant human APC (hAPC) variants that have enhanced anticoagulant effects. Selective mutagenesis of the phospholipid-binding Gla domain generated the mutant QGNSE DY-hAPC, which has increased affinity for negatively charged phospholipids membranes and enhanced anticoagulant activity [28,29]. The protease domain has also been subjected to mutagenesis aiming at improving the anticoagulant activity of APC. By replacing the so-called 148 loop in hAPC with the shorter bovine loop (the variant denoted hAPC: B148), the catalytic and anticoagulant activity was found to be enhanced [30]. By combining the mutations above, a new mutant QGNSE DY-hAPC: B148 was constructed that due to the combination of increased binding of the Gla-domain to phospholipid membranes and with increased catalytic and anticoagulant effect was highly anticoagulant [25]. Clotting experiments in rat plasma showed distinct dose dependent anticoagulant effect, especially with the mutant QGNSE DY-hAPC: B148 while WT hAPC showed almost no anticoagulant effect. The antithrombotic effect of the different variants of hAPC was then tested in a rat model of deep arterial injury. None of the APC variants had significant antithrombotic effects [25]. However, human PS was not combined with the APC in the experiments, which could explain the poor effects. This hypothesis gained support from additional evaluation of the anticoagulant effect of the hAPC variants in vitro using rat plasma, which demonstrated hPS to potentiate the anticoagulant activity of the two hAPC variants. This observation formed the basis for the present study, in which we explore the antithrombotic and anticoagulant effects of co-administration of hAPC and hPS using our arterial thrombosis model in the rat.

Materials and methods

Plasma Purified Proteins

Human APC was obtained from Chromogenix (Mölndal, Sweden). Human protein S was purified as earlier described [31]. Bovine protein C was purified as described [32]. It was activated as previously described in detail [16]. Bovine protein S was purified as described [33], with modifications as in [31].

Recombinant Proteins

The QGNSE DY-hAPC carrying the Gla-domain mutations H10Q/S11G/S12N/D23S/Q32E/N33D/H44Y was prepared as described [28]. The hAPC: B148 mutant was constructed as described earlier [30]. In brief, the 148 loop in hAPC, GWGYHSSREKEA KR (the underlined amino acids correspond to positions 303–310), was changed to the four residues shorter corresponding loop in bAPC (GWGYRDET KR). The QGNSE DY-hAPC: B148 mutant was prepared as described [25]. Recombinant hPS was produced as previously described [34].

In vitro anticoagulant analyses

The in vitro anticoagulant effects of bAPC, hAPC, and the recombinant hAPC variants with or without protein S (as indicated in the figures) were investigated in rat plasma and in human plasma. Rat plasma was acquired from male Sprague-Dawley albino rats, and the plasma was handled in the same way as in the in vivo experiments (see below). Human citrated plasma was acquired from a mixture of plasma from 30–40 volunteers without known coagulation defects. In the APTT system, 50 μl of plasma with or without added bPS or hPS 10 μg/ml (concentration in plasma) were mixed with 50 μl Platelet LS (Biomerieux, Marcy l’Etoile, France) and incubated for 180 seconds at a temperature of 37°C before initiation of coagulation by adding 50 μl of CaCl₂ 30 mM with different concentrations of the APC variants (0, 5, 10, 20, 40, 80, 160 and 320 nM). The experiment was performed three times in duplicate and the mean values of each pair of analyses are presented. In the prothrombin time (PT), 50 μl plasma, with or without added bPS or hPS 10 μg/ml was incubated for 180 seconds at a temperature of 37°C before activation of coagulation by addition of 100 μl tissue factor reagent (Simplastin Excel from Biomerieux), diluted 1:50 in 1 × TBS+0.1% BSA+10 mM Ca^{2+} (1 × TBS = 50 mM Tris-HCl, 0.15 M NaCl, pH 7.5), containing increasing concentrations of APC variants (0, 5, 10, 20, 40, 80, 160 and 320 nM). The experiment was performed twice and the assays were made in duplicate in one of the experiments and once in the other. The mean values of the
double test and the single values of the other experiment are presented. The clotting times were measured up to 200 seconds using an Amelung KC 10 instrument (Amelung Heinrich, Lemgo, Germany).

**APC inhibition in plasma**
The chromogenic substrate S-2366 (kindly provided by Chromogenix, Milano, Italy) was used to study the kinetics of inhibition of the APC-variants in rat plasma at room temperature. The concentration of added APC to rat plasma was 50 nM and at different time points, the remaining APC activity was measured with S-2366 hydrolysis at 405 nm in an Automated Microplate Reader (model EL 808, Bio-Tek Instruments, Winooski, VT, U.S.A.).

**Arterial thrombosis model**
Sixty Sprague-Dawley male albino rats with a mean body weight of 263 grams (range 226–312 grams) were used. The Research Ethics Committee at Lund University approved the experiments. The experimental model of deep arterial injury was performed exactly as previously described [19,25]. In summary, the right femoral vein was cannulated for infusion of randomized substances and blood sampling. After clamping the left common carotid artery, a longitudinal incision exposed the inner vessel layer. A five millimeter endarterectomy was performed by microsurgical technique and deep vessel layers were exposed. The arteriotomy was closed with micro sutures. The clamps were removed and the vessel was reperfused. All blood emerging from the suture line was collected by preweighed cylindrical swabs to calculate the total blood loss from the arteriotomy. Vessel patency was evaluated 31 minutes after reperfusion with the standard microvascular empty-refill test and the vessel was classed as open or occluded. One surgeon (K.M.) performed all operations. The mean total time for the experiments was 92 minutes (range 84–103).

**Experimental Protocol**
In a blind randomized study, 60 rats were divided into 5 groups that were treated either with recombinant hPS 0.6 mg/kg (n = 10), WT hAPC 0.8 mg/kg + hPS 0.6 mg/kg (n = 10), QGNSEDY-hAPC 0.8 mg/kg + hPS 0.6 mg/kg (n = 10), QGNSEDY-hAPC: B148 0.8 mg/kg + hPS 0.6 mg/kg (n = 10) or vehicle only (n = 20). The randomized substances were stored in 1.5 ml coded Eppendorf plastic tubes (Sarstedt, Numbrecht, Germany) at -78°C and thawed to room temperature immediately before use. The substances were delivered as intravenous weight-adjusted bolus injections after completing the vascular injury, one minute before reperfusion. The infusion volume was 0.21 ml per 100-gram animal weight in all groups. The vehicle was 20 mM Tris-HCl, 0.15 M NaCl, pH 7.5, containing 0.2% BSA.

**Ex vivo coagulation analyses**
Blood samples (0.9 ml) were drawn from the femoral vein of the rats 1 minute before injection of the substance, then 2 and 30 minutes after reperfusion. Before each sample was collected, 0.5 ml of blood was drawn into a separate syringe and wasted. After every 0.9-ml sample was collected, 0.5 ml of saline was injected with another syringe to clear the catheter from blood. The samples were collected with a 2-ml plastic syringe (Plastipak; Becton Dickinson AB, Hägersten, Stockholm, Sweden) prefilled with 0.1 ml of 3.8% 0.13 M sodium citrate. The samples were immediately transferred to 1.5-ml Eppendorf plastic tubes and centrifuged at 14 000 rpm for 3 minutes (Mikro 12/24; Hettich Zentrifugen, Tuttingen, Germany). The plasma was separated with a pipette and put in two Eppendorf tubes with 300 μl of plasma in each. The tubes were put in a box containing pellets of carbon acid ice. After completion of the daily experiments, the plasma samples were transferred to a freezer maintaining a temperature of -78°C. The APTT and PT assays were done as described above with the exception that the Platelin LS was diluted 1:2 in TBS+ 0.1% BSA.

**Statistical Methods**
Patency rates were compared using Fisher’s exact test and bleeding weights with the Mann-Whitney test. Statistics were calculated using StatXact 4.0.1 software (Cytel Software Corp., Cambridge, Mass., U.S.A.). Two-sided p-values are presented and p-values <0.05 were considered statistically significant. No correction was made for multiple testing.

**Results**
**Anticoagulant effects of human APC variants in rat plasma**
Plasma-derived human APC, even when combined with human PS, yielded only a very small anticoagulant effect in rat plasma (Fig. 1). Similar results were obtained with recombinant WT APC and PS (Fig. 2). In contrast, in the presence of hPS, both QGNSEDY-hAPC and QGNSEDY-hAPC:B148 plus hPS approximately doubled the clotting time in the whole dose range tested (Fig 2).

**Rate of inhibition of APC variants in rat plasma**
The APC variants were mixed with rat plasma and the rate of inhibition of enzymatic activity measured (Fig. 3). The recombinant hAPC variants showed similar t1/2 around 20 minutes. Bovine APC, used as control, is inhibited at a slower rate with t1/2 of 35 minutes.

**Antithrombotic effect of hAPC variants?**
In the groups with WT hAPC+hPS or QGNSEDY-hAPC+hPS there was only one vessel open in each group. In the group with QGNSEDY-hAPC:B148+hPS, there was a trend towards antithrombotic effect as the patency rate was 4/10 (Fig 4A), but the difference to the control group
**Figure 1**

*In Vitro* anticoagulant response in rat plasma produced by plasma purified proteins. Increasing concentrations of bAPC or hAPC, with or without PS (10 μg/ml), in rat (A+C) or human plasma (B+D) measured with either the APTT reagent Platelin LS (A+B) or with the tissue-factor reagent Simplastin Excel (C+D). Mean values and standard deviation (error bars) are presented. The indicated concentrations of APC refer to the concentrations of the proteins in the APC-containing solutions that were used to initiate the clotting reactions, as detailed in the Methods section. The experiments with bAPC in rat plasma, with or without bPS, were presented in one of our previous studies [19] and the same results are presented here again in the same figure as the experiments with hAPC, with or without hPS, in both plasma types to make comparisons possible.
was not statistically significant \( (p = 0.14) \). The administration of hPS alone did not give any antithrombotic effect, the patency rate \((2/10\ \text{vessels})\) being similar to that of the control group \((2/20)\).

**Arteriotomy bleeding**

Administration of the different hAPC variants did not increase the arteriotomy bleeding compared to controls (Fig 4B). The cumulative arteriotomy bleeding during 31 minutes of observation was 1.1 grams (median) in the control group and 0.68 to 1.3 grams (medians) in the treatment groups. There was no statistically significant difference between the groups.

**Ex vivo coagulation analyses**

Administration of WT hAPC+hPS or hPS alone only slightly increased the clotting time (Fig 5A and 5B). Three minutes after injection of QGNSEDY-hAPC+hPS, the APTT and PT times increased 1.6 and 1.3 times, respectively. Corresponding values for QGNSEDY-hAPC:B148+hPS were 1.9 and 1.5 times. At 31 minutes after injection, the clotting times had almost returned to baseline levels in all groups (Fig. 5A and 5B).

**Discussion**

In our arterial thrombosis model in the rat, we find no antithrombotic effect of WT hAPC \[25\] even when we now give WT hAPC together with hPS. This is in contrast to results obtained in other thrombosis models in the rat, where hAPC has been reported to have antithrombotic properties \[20-24\]. The discrepancy may be due to differences in the type of vascular trauma. Our model includes a crude vascular trauma producing occlusive thrombi, and is quite resistant to antithrombotic intervention. It was developed to mimic conditions encountered in clinical vascular surgery. However, despite being arterial and
Involving primary hemostasis events, the model is also dependent on activation of blood coagulation and sensitive to anticoagulant substances [19, 26, 27].

The interaction between APC and PS is species-specific, which makes cross-species studies more difficult. However, it can also be an advantage and help clarify the importance of the cofactor function of PS. Thus, we have found bAPC to be a highly efficient antithrombotic agent in arterial thrombosis models with patency rates reaching 90–100% in both rat and rabbit, but only when bovine PS was given together with the bAPC [17-19]. This agrees with results of clotting assays, in which bAPC is highly anticoagulant in human, rabbit, and rat plasmas in the presence of bovine PS, but not in its absence [35, 36]. Human APC has shown anticoagulant effects in bovine, baboon and rabbit plasmas, suggesting that hAPC is able to interact with PS from different origin [33-37]. However,

**Figure 3**

**Inactivation of APC in rat plasma.** The different APC variants were added to rat plasma and at various time points; the remaining amidolytic activity was measured at 405 nm using the synthetic substrate S-2366. The absorbance reading of plain rat plasma was subtracted from the mean of two absorbance readings at each time point and the difference was used for presentation. The three recombinant hAPC variants were tested in one experiment and bAPC was tested in another experiment and the results were combined into one figure.
we now find almost no hAPC cofactor effect of hPS in rat plasma.

As hAPC was inactive in our thrombosis model, we were interested in evaluating the antithrombotic effects of two hAPC variants (QGNSEDY-hAPC and QGNSEDY-hAPC: B148) having enhanced anticoagulant activity. These mutants, despite giving an anticoagulant response in rat plasma, did not give a significant antithrombotic effect when given alone in our arterial thrombosis model, i.e. no co-administration of hPS [25]. We have now investigated the possible beneficial effects of co-infusion of the hAPC variants with hPS. The results show that neither form of hAPC produced significant antithrombotic effects and although QGNSEDY-hAPC: B148 increased the vessel patency rate compared to the controls, the difference did not reach significance.

The discrepant findings in the thrombosis model between human and bovine APC are interesting. In coagulation tests performed both in vitro and ex vivo, hAPC plus hPS yielded stronger anticoagulant response [19] than the combination of hAPC variants plus hPS (Fig 2 and 5), which should contribute to the lower anti-thrombotic effects of the hAPC variants. Another factor is the difference in elimination kinetics between the bovine and human APC, the half-life of hAPC in rat plasma being almost twice as long as those of the hAPC variants (Fig. 3). APC is inhibited in plasma mainly by two serpins, α1-antitrypsin (α1-AT) and protein C inhibitor (PCI) [38,39].
Bovine APC has been shown to be resistant to inhibition by α1-AT in vitro and the structural requirements for this has been investigated [40]. The low anticoagulant effect of hAPC in rat plasma may also suggest that rat FVa and FVIIa are poor substrates for hAPC. In this context it is interesting that more than ten-fold higher concentration of hAPC was needed to inactivate rat FVa as compared to human FVa [41].

Conclusion
In conclusion, in an arterial thrombosis model in the rat we find no significant antithrombotic effects of neither WT-hAPC nor hAPC variants with enhanced anticoagulant activity even when the human APC cofactor PS was co-injected. Our results underline the difficulties in using reagents across the species borders and calls for the creation of corresponding APC variants with the same species background as the animals that are used in the thrombosis model.

Abbreviations
WT: wild type; APC: activated protein C; PS: protein S; APTT: activated partial thromboplastin time; PT: prothrombin time; TBS: tris-buffered saline; BSA: bovine serum albumin.

Competing interests
KM and BA report no competing interest. BD is inventor of the APC variants on pending patent applications.

Authors’ contributions
KM performed all surgical procedures, participated in planning of the study, interpreted results and participated in writing of the manuscript; BA participated in the development of the thrombosis model, in the planning of the study, interpretation of results, and in the preparation of the manuscript; BD participated in the planning of the study, provided reagents, performed in vitro assays, interpreted results and participated in the writing of the paper.

Acknowledgements
We thank especially Mrs. Ing-Marie Persson and also Mrs. Astra Anderson at the Department of Laboratory Medicine, Clinical Chemistry, University Hospital, Malmö for preparation of the proteins and performing the plasma analyses. We also thank Associate Professor Ulf Stromberg, Dept. of Occupational and Environmental Medicine, Lund University, for help with the statistical analyses. This work was supported by grants from the Swedish Science Council (# 07143), the Osterlund’s Foundation, the Påhlsson’s Foundation and by research funds from the University Hospital, Malmo (B.D., B.A.), and by the Thüréus Foundation in Uppsala and by The Royal Physiographic Society in Lund (K.M).

References
1. Esmon CT: Regulation of blood coagulation. Biochim Biophys Acta 2000, 1477:349-360.
2. Esmon CT: The protein C pathway. Chest 2003, 124:26S-32S.

Figure 5
Ex vivo anticoagulant response in rat plasma. The coagulation times were measured with either the APTT reagent Platelin LS (A) or with the tissue-factor reagent Simplastin Excel (B). Baseline values were obtained at -2 minutes. The randomized substances were injected at -1 minutes, followed by clamp release at 0 minutes (n = 10 in all treatment groups, n = 20 in the control group). The medians are shown.
24. Yamashita T, Matsuoka A, Funatsu A, Yamamoto J: The antithrombotic effect of human activated protein C on He-Ne laser-induced thrombosis in rat mesenteric microvessels. *Thromb Res* 1994, 75:33-40.

25. Malm K, Arnjots B, Persson IM, Dahlback B: Antithrombotic and anticoagulant effects of wild type and Gla-domain mutated human activated protein C in rats. *Thromb Res* 2007, 120:531-539.

26. Malm K, Dahlback B, Arnjots B: Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. *Plast Reconstr Surg* 2003, 111:1659-1666.

27. Soderstrom T, Hedner U, Arnjots B: Active site-inactivated factor Vlla prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury. *J Vasc Surg* 2001, 33:1072-1079.

28. Sun YH, Shen L, Dahlback B: Gla domain-mutated human protein C exhibiting enhanced anticoagulant activity and increased phospholipid binding. *Blood* 2003, 101:2277-2284.

29. Sun YH, Tran S, Norstrom EA, Dahlback B: Enhanced rate of cleavage at Arg-306 and Arg-506 in coagulation factor Va by Gla domain-mutated human-activated protein C. *J Biol Chem* 2005, 279:47528-47535.

30. Shen L, Villoutreix BO, Dahlback B: Interspecies loop grafting in the protoplast domain of human protein C yielding enhanced catalytic and anticoagulant activity. *Thromb Haemost* 1999, 82:1078-1087.

31. Dahlback B: Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin. *Biochem J* 1983, 209:837-846.

32. Stenflo J: A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. *J Biol Chem* 1976, 251:355-363.

33. Stenflo J, Jonsson M: Protein S, a new vitamin K-dependent protein from bovine plasma. *FEBS Lett* 1979, 101:377-381.

34. He X, Shen L, Villoutreix BO, Dahlback B: Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin K-dependent protein S determining specificity of the activated protein C cofactor function. *J Biol Chem* 1998, 273:27449-27458.

35. Dahlback B: Inhibition of protein Cα cofactor function of human and bovine protein S by C4b-binding protein. *J Biol Chem* 1986, 261:12022-12027.

36. He X, Shen L, Dahlback B: Expression and functional characterization of chimeras between human and bovine vitamin-K-dependent protein-S-defining modules important for the specificity of the activated protein C cofactor activity. *Eur J Biochem* 1995, 227:433-440.

37. Taylor FB Jr, Chang A, Esmon CT, D’Angelo A, Vigano-D’Angelo S, Blick KE: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. *J Clin Invest* 1987, 79:918-925.

38. Heeb Mj, Griffin Jh: Physiologic inhibition of human activated protein C by alpha 1-antitrypsin. *J Biol Chem* 1988, 263:11613-11616.

39. Suzuki K, Nishioka J, Hashimoto S: Protein C inhibitor. Purification from human plasma and characterization. *J Biol Chem* 1983, 258:163-168.

40. Shen L, Dahlback B, Villoutreix BO: Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin. *Biochemistry* 2000, 39:2853-2860.

41. Katsuura Y, Mochizuki T, Tamura M, Hoshide S, Kiyoki M, Nakagaki T, Miyamoto S: Species specificity of anticoagulant activity of activated human protein C: involvement of factor V as well as protein S. *Thromb Res* 1996, 82:147-157.

3. Dahlback B: The importance of the protein C system in the pathogenesis of venous thrombosis. *Hematology* 2005, 11:13-19.

4. Dahlback B, Villoutreix BO: Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. *Arterioscler Thromb Vasc Biol* 2005, 25:1311-1320.

5. Griffin JH, Fernandez JA, Gale AJ, Mosnier LO: Activated protein C. *J Thromb Haemost* 2007, 5(Suppl 1):73-80.

6. Griffin JH, Fernandez JA, Mosnier LO, Liu D, Cheng T, Guo H, Zlokovic BV: The promise of protein C. *Blood Cells Mol Dis* 2006, 36:211-216.

7. Aich M, Borgel D, Gaussem P, Emmerich J, Alhenc-Gelas M, Gandrille S: Protein C and protein S deficiencies. *Semin Hematol* 1997, 34:205-216.

8. Dahlback B: Advances in understanding pathogenic mechanisms of thrombophilic disorders. *Blood* 2008, 112:19-27.

9. Warkentin TE, Arnjots B, Dahlback B: Active enzyme-activated protein C by protein S. The role of phospholipid in factor Va inactivation. *J Biol Chem* 1981, 256:11128-11131.

10. Yegneswaran S, Smirnov MD, Safa O, Esmon NL, Esmon CT, Johnson AE: Relocating the active site of activated protein C eliminates need for its protein S cofactor. A fluorescence resonance energy transfer study. *J Biol Chem* 1999, 274:3402-3406.

11. Gruber A, Griffin JH, Barker LA, Hanson SR: Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. *Blood* 1989, 73:639-642.

12. Gruber A, Hanson SR, Kelly AB, Yan BS, Bang N, Griffin JH, Barker LA: Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. *Circulation* 1990, 82:378-385.

13. Gruber A, Barker LA, Hanson SR, Kelly AB, Griffin JH: Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. *Circulation* 1991, 84:2454-2462.

14. Hanson SR, Griffin JH, Barker LA, Kelly AB, Esmon CT, Gruber A: Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. *J Clin Invest* 1993, 92:2002-2012.

15. Hanson SR, Barker LA: Baboon models of acute arterial thrombosis. *Thromb Haemost* 1987, 58:801-805.

16. Arnjots B, Bergqvist D, Dahlback B: Inhibition of microthrombosis by activated protein C in a rabbit model. *Thromb Haemost* 1994, 72:415-420.

17. Arnjots B, Dahlback B: Protein S as an in vivo cofactor to activated protein C in prevention of microvascular thrombosis in rabbits. *J Clin Invest* 1995, 95:1897-1903.

18. Arnjots B, Dahlback B: Antithrombotic effects of activated protein C and protein S in a rabbit model of microvascular thrombosis. *Arterioscler Thromb Vasc Biol* 1995, 15:937-941.

19. Malm K, Dahlback B, Arnjots B: Prevention of thrombosis following deep arterial injury in rats by bovine activated protein C requiring co-administration of bovine protein S. *Thromb Haemost* 2003, 90:227-234.

20. Araki H, Nishi K, Ishihara N, Okajima K: Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries. *Thromb Res* 1991, 62:209-216.

21. Hashimoto M, Watanabe S, Otawa K, Ohta Y, Kishi T, Okamoto T, Giddings JC, Yamamoto J: Enhanced thrombolysis induced by argatroban or activated protein C in the presence or absence of staphylokinase, measured in an in vivo animal model using mesenteric arterioles. *Haemostasis* 2001, 31:80-89.

22. Hashimoto M, Yamashita T, Otawa K, Watanabe S, Giddings JC, Yamamoto J: Enhancement of endogenous plasminogen activator-induced thrombolysis by argatroban and APC and its control by TAFI, measured in an arterial thrombolysis model in vivo using rat mesenteric arterioles. *Thromb Haemost* 2002, 87:110-113.

23. Smirnov MD, Pzych MV, Borovkik DV, Atozorh childova AN, Dobrovolsky AB, Golubych VL, Gratsiansky NA: Low doses of activated protein C delay arterial thrombosis in rats. *Thromb Res* 1990, 57:645-650.

24. Yamashita T, Matsuoka A, Funatsu A, Yamamoto J: The antithrombotic effect of human activated protein C on He-Ne laser-induced thrombosis in rat mesenteric microvessels. *Thromb Res* 1994, 75:33-40.